We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

TJX:NYSETJX Companies, Inc. (The) Analysis

Data as of 2026-05-27 - not real-time

$156.78

Latest Price

5/10Risk

Risk Level: Medium

Executive Summary

TJX delivered a strong earnings beat with revenue up 9.2% YoY to $61.6 B and EPS climbing to $5.13, while management raised FY 2027 guidance and lifted the dividend to $1.92 per share, reflecting a 33% payout ratio and a 27.5% five‑year dividend growth rate. Operating margins remain healthy at 11.8% and free cash flow exceeds $4.3 B, supporting the impressive 61% ROE and a robust balance sheet with ample cash. Analyst sentiment is bullish, with a “strong buy” consensus and a median price target near $176, implying roughly 13% upside.
On the technical side, the stock trades just above its 20‑day SMA (≈$153.8) and near the 50‑day SMA (≈$156.6), with a neutral RSI of 53 and a bullish MACD histogram. Volume is increasing, and the MACD signal turned bullish, suggesting short‑term momentum could push the price toward the $160.9 resistance. However, the DCF fair value of $67 indicates the market is currently overvalued, so investors should weigh the valuation gap against the strong fundamentals and dividend sustainability.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Bullish MACD histogram with increasing volume
  • Price trading just below resistance at $160.9
  • Neutral RSI indicating no immediate overbought pressure

Medium Term

1–3 years
Neutral
Model confidence: 7/10

Key Factors

  • Strong revenue growth (9.2%) and EPS beat
  • Raised FY 2027 guidance and dividend increase
  • Valuation still above DCF fair value, limiting upside

Long Term

> 3 years
Positive
Model confidence: 8/10

Key Factors

  • Sustained high ROE (61%) and solid free cash flow generation
  • Consistent dividend growth and sustainable payout ratio
  • Competitive off‑price retail model with resilient consumer demand

Key Metrics & Analysis

Financial Health

Revenue Growth9.20%
Profit Margin9.40%
P/E Ratio30.6
ROE61.25%
ROA13.87%
Debt/Equity136.31
P/B Ratio17.0
Op. Cash Flow$7.6B
Free Cash Flow$4.3B

Technical Analysis

TrendNeutral
RSI53.6
Support$146.14
Resistance$160.89
MA 20$153.76
MA 50$156.65
MA 200$150.29
MACDBullish
VolumeIncreasing
Fear & Greed Index91.91

Valuation

Fair Value$67.26
Target Price$177.63
Upside/Downside13.30%
GradeOvervalued
TypeGrowth
Dividend Yield1.21%

Risk Assessment

Beta0.30
Volatility23.58%
Sector RiskMedium
Reg. RiskLow
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.